Actuate Therapeutics, Inc (ACTU)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Actuate Therapeutics, Inc (ACTU) is down 70.3% since the beginning of the year. At $2 per share, ACTU is trading 80.5% below its 52-week high of $9.

Actuate Therapeutics, Inc (ACTU) has returned -70.26% so far this year and -81.33% over the past 12 months.

Based on dividend-adjusted daily data since Aug 13, 2024, ACTU's average daily return is -0.20%, while the average monthly return is -4.30%.

Historically, 39% of months were positive and 61% were negative. The best month was Apr 2025 with a return of +35.9%, while the worst month was Jun 2025 at -48.7%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 4 months.

On a daily basis, ACTU closed higher 45% of trading days. The best single day was Apr 22, 2026 with a return of +22.7%, while the worst single day was Sep 10, 2025 at -19.2%.

Actuate Therapeutics, Inc has an annualized alpha of -51.31%, beta of 1.11, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since August 14, 2024.

• This stock participated in 301.14% of S&P 500 Index downside but only -88.15% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ACTU ranks 3 for risk / return — in the bottom 3% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Actuate Therapeutics, Inc (ACTU) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Actuate Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Actuate Therapeutics, Inc was 85.55%, occurring on Apr 10, 2026. The portfolio has not yet recovered.

The current Actuate Therapeutics, Inc drawdown is 84.71%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Actuate Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Actuate Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.